Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Rochester, NY
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Burlington, NC
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Burlington, NC
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Canfield, OH
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Canfield, OH
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
Gabrail Cancer Center
mi
from
Canton, OH
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Portland, OR
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Portland, OR
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Lancaster, PA
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Lancaster, PA
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Spartanburg, SC
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Round Rock, TX
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Round Rock, TX
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Long Beach, CA
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Miami, FL
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Orange City, FL
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Orange City, FL
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Tampa, FL
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Peoria, IL
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Peoria, IL
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Skokie, IL
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Skokie, IL
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigator
mi
from
Flat Rock, NC
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigator
mi
from
Flat Rock, NC
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Wilmington, NC
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Wilmington, NC
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Winston Salem, NC
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated:  2/4/2016
GTx Investigative Site
mi
from
Sandusky, OH
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
Status: Enrolling
Updated: 2/4/2016
GTx Investigative Site
mi
from
Sandusky, OH
Click here to add this to my saved trials
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  2/4/2016
The University of California Irvine
mi
from
Orange, CA
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 2/4/2016
The University of California Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  2/4/2016
Augusta University
mi
from
Augusta, GA
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 2/4/2016
Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  2/4/2016
Massachusetts General Hospital
mi
from
Boston, MA
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 2/4/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  2/4/2016
Methodist Neurological Institute
mi
from
Houston, TX
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 2/4/2016
Methodist Neurological Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Shared Decision Making to Improve Care and Outcomes for Children With Autism
Shared Decision Making to Improve Care and Outcomes for Children With Autism
Status: Enrolling
Updated:  2/4/2016
Cincinnati Children's Medical Center
mi
from
Cincinnati, OH
Shared Decision Making to Improve Care and Outcomes for Children With Autism
Shared Decision Making to Improve Care and Outcomes for Children With Autism
Status: Enrolling
Updated: 2/4/2016
Cincinnati Children's Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)
The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  2/4/2016
UT Southwestern Medical Center, School of Health Professions
mi
from
Dallas, TX
The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)
The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 2/4/2016
UT Southwestern Medical Center, School of Health Professions
mi
from
Dallas, TX
Click here to add this to my saved trials
Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?
Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?
Status: Enrolling
Updated:  2/4/2016
Flagler Hospital
mi
from
St. Augustine, FL
Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?
Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?
Status: Enrolling
Updated: 2/4/2016
Flagler Hospital
mi
from
St. Augustine, FL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 110
mi
from
Berkeley, CA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 110
mi
from
Berkeley, CA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 122
mi
from
Long Beach, CA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 122
mi
from
Long Beach, CA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 112
mi
from
Sacramento, CA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 112
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 120
mi
from
San Francisco, CA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 120
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 127
mi
from
Denver, CO
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 127
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 114
mi
from
Maitland, FL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 114
mi
from
Maitland, FL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 135
mi
from
Ormond Beach, FL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 135
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 148
mi
from
Sarasota, FL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 148
mi
from
Sarasota, FL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 147
mi
from
Tampa, FL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 147
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 147
mi
from
Tampa, FL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 147
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 113
mi
from
Northbrook, IL
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 113
mi
from
Northbrook, IL
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 163
mi
from
Kansas City, KA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 163
mi
from
Kansas City, KA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 142
mi
from
Lenexa, KA
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 142
mi
from
Lenexa, KA
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 169
mi
from
Lexington, KY
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 169
mi
from
Lexington, KY
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 149
mi
from
Louisville, KY
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 149
mi
from
Louisville, KY
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 159
mi
from
Detroit, MI
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 159
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 167
mi
from
East Lansing, MI
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 167
mi
from
East Lansing, MI
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 137
mi
from
Golden Valley, MN
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 137
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 121
mi
from
Saint Louis, MO
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 121
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 170
mi
from
Las Vegas, NV
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 170
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 162
mi
from
West Long Branch, NJ
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 162
mi
from
West Long Branch, NJ
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 140
mi
from
Johnson City, NY
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 140
mi
from
Johnson City, NY
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 143
mi
from
Raleigh, NC
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 143
mi
from
Raleigh, NC
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 107
mi
from
Akron, OH
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 107
mi
from
Akron, OH
Click here to add this to my saved trials
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated:  2/4/2016
Receptos Study Site 164
mi
from
Columbus, OH
Phase 3 Study of RPC1063 in Relapsing MS
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
Status: Enrolling
Updated: 2/4/2016
Receptos Study Site 164
mi
from
Columbus, OH
Click here to add this to my saved trials